NOMINATED FOR THE COPENHAGEN BUSINESS AWARD FOR A CONSECUTIVE YEAR
INFUSER is nominated for the City of Copenhagen Business Award (Københavns Kommune Erhvervspris 2017) for a second year in a row.
Last year, Copenhagen Municipality introduced a new tradition to reward companies that make a unique difference for local and global communities. INFUSER won the prize of innovation in 2016 – we are now honored to consecutively be nominated for the same prize again. On the 7th of June 2017, 13 Danish companies with diverse sizes and business areas will candidate for Copenhagen’s Business award. The competition is divided in 3 categories, being “Innovation”, “Attractive City” and “Environment & Corporate Social Responsibility”. The winners will receive a business award along with a seat in Copenhagen’s Business Council to influence and direct the city’s political affairs. The Mayor of Copenhagen, Frank Jensen, appraises the contending companies for their contribution to sustainability, employment and creativity. Three categories that apply for our business aspirations – and we are pleased to be nominated for the prize of innovation.
WHY IS INFUSER NOMINATED FOR THE PRIZE OF INNOVATION 2017?
Because we have dedicated ourselves to saving lives with our groundbreaking invention – STERISAFETM Probased on the Full-Depth Disinfection Cycle (FDDC) technology. STERISAFETM Pro is the secure, effective, easy and sustainable answer to prevention and elimination of healthcare acquired infections (HAI). These infections are typically acquired in environments, where there is a lot of human interaction – e.g. hospitals, operating theaters, nursing homes, (daycare) centers and the like. STERISAFETM Pro bio-disinfects the air and all surfaces by killing bacteria, viruses and harmful fungi, whilst removing dangerous particles at the same time. No consumables and no harmful chemicals – just effective full-circle disinfection.
Every year, around 100.000 Danes (8-10% of those, who are hospitalized) are affected by an infection, they have acquired during a hospital stay. Of these, approximately 3.000 people die. At a European level, over 4 million patients are affected by HAI with 37.000 deaths as a result. These numbers are unacceptable, and they are costlier than any society or economy can bear. Therefore, INFUSER has set forth to prevent, control and minimize the occurrence of healthcare acquired infections once for all.